Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod
NCT06529406
·
clinicaltrials.gov ↗
PHASE4
Phase
RECRUITING
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Relapsing Multiple Sclerosis
Interventions
DRUG:
Ozanimod
Sponsor
University of Colorado, Denver